Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/11690/3673
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Boniatti, Márcio Manozzo | - |
dc.contributor.author | Nedel, Wagner Luis | - |
dc.contributor.author | Rihl, Marcos Frata | - |
dc.contributor.author | Schwarz, Patricia | - |
dc.contributor.author | Parolo, Edino | - |
dc.date.accessioned | 2023-11-16T18:14:12Z | - |
dc.date.available | 2023-11-16T18:14:12Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | BONIATTI, M. M. et al. Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial. Indian Journal of Critical Care Medicine, v. 27, n.7, 2023. Disponível em: https://www.ijccm.org/abstractArticleContentBrowse/IJCCM/64/27/7/33119/abstractArticle/Article. Acesso em: 16 nov. 2023. | pt_BR |
dc.identifier.uri | http://hdl.handle.net/11690/3673 | - |
dc.description.abstract | Background: Serotonin is a mediator of pulmonary hypoxic vasoconstriction. Experimental studies have shown that serotonin-mediated pulmonary vasoconstriction can be inhibited by cyproheptadine. The aim of this study is to assess whether treatment with cyproheptadine compared to usual care increases ventilatory support-free days during the first 28 days in patients with coronavirus disease 2019 (COVID-19) requiring ventilatory support. Materials and methods: This randomized, single-center, open-label clinical trial included patients who were admitted to the intensive care unit (ICU) requiring ventilatory support due to COVID-19. Patients allocated to the intervention group received cyproheptadine for 10 days. The primary outcome was ventilator-free days during the first 28 days. Results: Nineteen patients were randomized to receive cyproheptadine and 21 to the control group. The number of ventilatory support-free days during the first 28 days was not different between the two groups (15.0; 95% CI, 0.0–24.0 days in the control group vs 7.0; 95% CI, 0.0–19.0 days in the intervention group; p = 0.284). Conclusion: In patients with COVID-19 and in need of ventilatory support, the use of cyproheptadine plus usual care, compared with usual care alone, did not increase the number of ventilatory support-free days in 28 days. | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.rights | Open Access | - |
dc.subject | Coronavirus disease 2019 | pt_BR |
dc.subject | Cyproheptadine | pt_BR |
dc.subject | Intensive care unit | pt_BR |
dc.subject | Serotonin | pt_BR |
dc.subject | Ventilatory support | pt_BR |
dc.title | Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial | pt_BR |
dc.type | Artigo | pt_BR |
Aparece nas coleções: | Artigo de Periódico (PPGSDH) |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
IJCCM-27-517.pdf | Open Access | 345,25 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.